Takeda Pharmaceutical Company Limited (TKDA) — Cash Flow Quality Index
Takeda Pharmaceutical Company Limited (TKDA) has a Cash Flow Quality Index of 3.60x as of December 2025. Operating cash flow of €373.25 Billion exceeds net income of €103.64 Billion, indicating high earnings quality where cash backs reported profits. Explore Takeda Pharmaceutical Company Limited (TKDA) long-term investment share to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Takeda Pharmaceutical Company Limited Cash Flow Quality Index (2017–2025)
Historical Cash Flow Quality Index for Takeda Pharmaceutical Company Limited across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of Takeda Pharmaceutical Company Limited to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Takeda Pharmaceutical Company Limited (2017–2025)
Year-by-year earnings quality comparison for Takeda Pharmaceutical Company Limited. For live market cap and the full company financial profile, see market value of Takeda Pharmaceutical Company Limited.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 9.80x | €1.06 Trillion | €107.93 Billion | ▲ +363.4% |
| 2024 | 2.11x | €716.34 Billion | €338.87 Billion | ▼ -28.5% |
| 2023 | 2.96x | €977.16 Billion | €330.65 Billion | ▼ -39.5% |
| 2022 | 4.88x | €1.12 Trillion | €230.06 Billion | ▲ +19.5% |
| 2021 | 4.08x | €1.01 Trillion | €247.51 Billion | ▼ -73.0% |
| 2020 | 15.14x | €669.75 Billion | €44.24 Billion | ▲ +523.1% |
| 2019 | 2.43x | €328.48 Billion | €135.19 Billion | ▲ +20.2% |
| 2018 | 2.02x | €377.85 Billion | €186.89 Billion | ▼ -11.1% |
| 2017 | 2.27x | €261.36 Billion | €114.94 Billion | — |